Programme Thesis
This is a weekly curated roundup by OncoDaily (OncoGrants), not a single programme. The edition aggregates 10 currently open oncology funding opportunities spanning cancer immunotherapy, lung cancer drug resistance, ovarian cancer AI, nursing science, and a flagship pan-European consortium call. OncoGrants exists as a discovery feed for oncology researchers — its value is indexing, not administering, grants. Each listed opportunity is run by an independent funder with its own eligibility rules.
Selection Criteria
Because this is a multi-grant roundup, criteria vary by opportunity. The six grants with full detail published are:
• AACR Immuno-Oncology Fellowship ($60K/2yr): doctoral degree required; active postdoc/clinical research position; AACR membership; mentored project in cancer immunotherapy.
• ONF Emerging Investigator (up to $50K/1yr): registered doctorally-prepared oncology nurse; active in cancer care/education/research; no prior PI grant ≥$50K; experienced mentor required.
• AACR Career Development Awards for Diversity ($300K/3yr): doctoral degree; faculty appointment (asst. professor level) by Sept 2026; first independent position started 2020–2026; no prior federal R01/DP2; no clinical responsibilities.
• ACS Postdoctoral Fellowship ($66–70K stipend/yr, up to 3yr): ≤3 years postdoctoral experience; research at a U.S. academic/nonprofit institution; not enrolled in doctoral program.
• ACS Clinician Scientist Development Grant ($135K direct/yr, 3–5yr): full-time U.S. faculty with clinical responsibilities; not yet independent.
• LCRF Overcoming Resistance in Lung Cancer ($150K/2yr): non-profit academic/research institution required; postdoctoral researcher, clinical fellow, or early- to mid-career investigator; <7 years since initial faculty appointment; no prior LCRF funding in last 4 years; no geographic/citizenship restrictions.
• OCRA AI Accelerator Grant (in-kind AWS compute): consortium-based; lead investigators must be from U.S., UK, Canada, and Australia; significant AI integration required; research on OCRA's platform.
• Horizon Europe Cancer Mission Call 2026 (large consortia): typically requires minimum 3 legal entities from ≥3 EU Member States/associated countries; Nigeria is not an associated country, making solo or lead participation ineligible.
Past Winners / Cohort Profiles
Named past winners appear only for the LCRF mechanism, which is the most relevant data point: 2025 cohort included Ximeng Liu, PhD (UT MD Anderson Cancer Center) for research on EGFR PACC mutation resistance to firmonertinib in NSCLC — a classic translational molecular science profile with institutional backing at a top-tier U.S. cancer centre. LCRF has funded 450 grants totalling ~$53M since inception; its scientific advisory board (chaired by Kathryn O'Donnell, MD Southwestern) skews heavily toward bench-to-bedside translational researchers at R1 or cancer-centre institutions. AACR fellowship winners historically are postdoctoral researchers embedded at U.S./European academic medical centres with a named mentor PI. No publicly listed winners found for the ONF, OCRA, or Horizon Cancer Mission 2026 calls.
Ideal Candidate Fingerprint
The platonic ideal applicant across this roundup is a freshly minted PhD (or MD/PhD) in oncology, molecular biology, or cancer immunology, 0–5 years post-degree, embedded as a postdoctoral researcher or junior faculty member at a recognised non-profit academic medical centre in the U.S. or EU, with a defined mentor and an active bench project directly addressing cancer biology. For the Horizon Europe call, the ideal is a multi-institution European consortium with a LMIC partner (Nigeria can sometimes join as a third country). For LCRF specifically, the archetype is an early-career basic/translational scientist with drug-resistance data in lung cancer histologies.
Recommended Framing
The only mechanistically plausible entry point for Eniola in this roundup is the LCRF Research Grant, and it is a long-shot requiring deliberate reframing: her ODE/RK45 models and Bayesian MCMC framework operationalise a generalised 'consolidation threshold' for pharmacological resistance — a framework that, if explicitly extended to tyrosine-kinase inhibitor (TKI) resistance in NSCLC (where non-genomic, memory-consolidation-like adaptive resistance is poorly characterised), could be made lung-cancer adjacent. TOPOLOGIX's persistent-homology drug-protein interaction engine is also directly relevant to resistance-mechanism discovery. The strategic pitch would be: 'computational resistance modeller with a validated threshold-dynamics framework, seeking to apply it to TKI resistance in partnership with an LCRF-eligible lung cancer laboratory' — i.e., enter as a computational collaborator on a team application rather than as lead PI. However, she cannot apply solo: LCRF requires non-profit institutional affiliation, and ZYCO's status as a qualifying institution would need to be confirmed against their RFA language.
Watch Out
Multiple hard disqualifiers affect every grant in this roundup for Eniola as a solo applicant:
1. NO DOCTORAL DEGREE: Every named grant (AACR x2, ONF, ACS x2, LCRF) explicitly requires a PhD, MD, or doctoral equivalency. Eniola holds a B.Pharm (2:1). This is an absolute bar, not a waivable preference.
2. NO POSTDOCTORAL POSITION: ACS Postdoctoral Fellowship, AACR Immuno-Oncology Fellowship, and LCRF require an active postdoc or clinical fellow position at application. Eniola is an independent researcher and employed product manager.
3. NOT AN ONCOLOGY NURSE: ONF Emerging Investigator requires a registered, doctorally prepared oncology nurse. Eniola is a PCN-licensed pharmacist. Ineligible by role definition.
4. NOT AT A U.S. INSTITUTION: ACS Postdoctoral and ACS Clinician Scientist grants require a U.S.-based institution. Eniola is in Lagos, Nigeria.
5. NOT FACULTY: AACR Career Development Awards require an assistant-professor-level faculty appointment, which Eniola does not hold.
6. WRONG DISEASE AREA: All 10 grants fund cancer (oncology) research. Eniola's primary domain is addiction neuroscience and reward-memory pharmacology. There is no CCT-to-oncology publication in her portfolio.
7. OCRA CONSORTIUM STRUCTURE: Requires consortium leads from U.S./UK/Canada/Australia. Nigeria is excluded from the lead-institution requirement.
8. HORIZON EUROPE GEOGRAPHY: Nigeria is not an EU Member State or Horizon Europe associated country, precluding lead/coordinator eligibility.
9. INSTITUTIONAL AFFILIATION: ZYCO is not a verified non-profit academic/research institution in LCRF's sense; Synthcare (current employer) is a commercial entity. Independent researcher status does not meet 'non-profit academic institution' requirements for most grants listed.
Bottom line: Eniola faces a structural mismatch with this entire roundup. She should not invest application effort here unless she can identify a co-applicant/mentor at an LCRF-eligible institution who can carry the institutional lead role.